Evans E G, James I G, Seaman R A, Richardson M D
PHLS Mycology Reference Laboratory, Department of Microbiology, University of Leeds, U.K.
Br J Dermatol. 1993 Oct;129(4):437-42. doi: 10.1111/j.1365-2133.1993.tb03172.x.
In a multicentre, double-blind, randomized, parallel group study in general practice, 269 patients with clinically diagnosed fungal infection of the skin were treated with either naftifine (Exoderil) or 1% clotrimazole plus 1% hydrocortisone (CHC; Canesten HC) applied twice daily for 4 weeks. Only 115 patients were shown subsequently to have a fungal infection by laboratory tests; the others had inflammatory disease of unknown aetiology. In those with fungal disease, both treatments were equally effective in terms of mycological cure (negative microscopy and culture). Clinical results for all 265 patients showed no clinically identifiable difference between the two preparations in terms of resolution of the disease, indicating that naftifine does have anti-inflammatory activity at least equal to CHC. This study suggests that there is no clinical advantage in treating patients with clinically diagnosed fungal infection of the skin with an antimycotic/corticosteroid combination as opposed to naftifine alone.
在一项多中心、双盲、随机、平行组的全科医学研究中，269例临床诊断为皮肤真菌感染的患者，分别接受萘替芬（Exoderil）或1%克霉唑加1%氢化可的松（CHC；Canesten HC）治疗，每日两次，持续4周。随后经实验室检查，仅115例患者被证实患有真菌感染；其他患者患有病因不明的炎症性疾病。在患有真菌病的患者中，两种治疗方法在真菌学治愈（显微镜检查和培养阴性）方面同样有效。所有265例患者的临床结果显示，两种制剂在疾病缓解方面没有临床可识别的差异，这表明萘替芬至少具有与CHC相当的抗炎活性。这项研究表明，与单独使用萘替芬相比，用抗真菌药/皮质类固醇联合治疗临床诊断为皮肤真菌感染的患者没有临床优势。
